Oppenheimer Initiates Outperform Coverage on Palisade Bio with $8 Price Target
Strong bullish case for its oral IBD therapy ahead of Phase 2 data.
/ 6 items
#PALI↓
Palisade Bio Stock Surges on Positive FDA Clearance for Next-Gen IBD Therapy
The FDA has cleared Palisade Bio’s investigational new drug application for PALI-2108. The company will now start its Phase 2 ASCENTRA-UC trial in H2 2026.
Wolfe Research Initiates Coverage on Palisade Bio and Avalo Therapeutics with Strong Buy Calls
Wolfe Research: PALI “Outperform” ($7) eyes 2027 ulcerative colitis trial; AVTX “Outperform” ($48) waits May LOTUS Phase 2 readout.
H.C. Wainwright Initiates Buy Rating on Palisade Bio with $7 Target
Analysts say PALI-2108 offers better safety and efficacy for ulcerative colitis compared to older PDE4 inhibitors.
Palisade Bio Secures Japanese Patent for PALI-2108 IBD Treatment
Palisade Bio (PALI) receives Japan patent for PALI-2108, a targeted PDE4 inhibitor for ulcerative colitis and Crohn's disease, with Phase 2 trials planned for 2026.
Piper Sandler Backs Palisade Bio Ahead of Key Crohn’s Data
Piper Sandler starts coverage on Palisade Bio with an Overweight rating and a $25 target, citing strong potential for its Crohn’s disease drug PALI-2108.